CG Oncology Shares Jump 20% After Quarterly Results Beat Estimates

CG Oncology shares rose 20% to $77.96 on Friday after the cancer treatment developer reported a third-quarter loss per share smaller than analysts expected and revenue above forecasts. The stock has gained 87% this year.

November 6, 2026, 10:00 PM 259 0

CG Oncology Shares Jump 20% After Quarterly Results Beat Estimates

The company reported a loss of $56.9 million, or 64 cents a share, compared with a loss of $43.8 million, or 57 cents a share, a year earlier. Wall Street had projected a loss of 84 cents a share.

Revenue fell to $1.6 million from $1.7 million a year earlier, but exceeded analysts’ estimate of $500,000. CG Oncology expects to share data from studies in November and December. In October, it added Isabel Kalofonos as Chief Commercial Officer.

When reusing this material a link to Money Talk is required.